Getinge AB stock (SE0000202624): medical technology player in focus after Q1 2025 results

Getinge AB has reported its Q1 2025 figures and updated investors on demand trends in critical care and surgical workflows. What drives the Swedish medtech group’s business – and what should US-oriented investors know about the stock?

Getinge AB, the Swedish medical technology group, recently published its results for the first quarter of 2025 and commented on demand trends in intensive care, surgical workflows and life science equipment, according to a quarterly report released on April 19, 2025 on the company’s investor website Getinge Q1 2025 report as of 04/19/2025. The figures provide fresh insights into how hospitals and research institutions are investing after the pandemic years and how this affects the company’s sales and margins.

As of: 05/19/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Getinge B
• Sector/industry: Medical technology, healthcare equipment
• Headquarters/country: Gothenburg, Sweden
• Core markets: Hospitals, intensive care units, surgical centers, life science labs
• Key revenue drivers: Ventilators, operating room equipment, sterile reprocessing, heart-lung machines, consumables and service
• Home exchange/listing venue: Nasdaq Stockholm (GETI B)
• Trading currency: Swedish krona (SEK)

Getinge AB: core business model

Getinge AB focuses on products and solutions that support critical moments in healthcare, such as intensive care, surgery and sterilization of instruments. The group’s structure is organized around business areas covering acute care therapies, surgical workflows and life science-related applications. This allows the company to offer integrated solutions that span equipment, software, disposables and after-sales service, according to its company profile updated on the corporate website Getinge company information as of 03/15/2025.

In practice, Getinge AB generates revenue when hospitals invest in ventilators, anesthesia machines, heart-lung support systems and advanced patient monitoring technology. Additional income comes from operating room tables, lights and related infrastructure for surgical suites. The company also supplies washers, sterilizers and tracking software that ensure surgical instruments are reprocessed safely and meet regulatory standards, which is an essential but often less visible part of modern hospital operations.

A significant part of the business model rests on recurring sales from consumables, service contracts and software updates. Once devices are installed in an intensive care unit or operating room, hospitals typically sign multi-year service agreements for maintenance and upgrades. This creates a steady revenue stream that partly balances the cyclicality of larger equipment orders. For a global medtech player such as Getinge AB, a broad installed base in Europe, North America and Asia is therefore strategically important.

Main revenue and product drivers for Getinge AB

Getinge AB’s revenue mix is strongly influenced by capital expenditure cycles in hospitals and by healthcare spending levels in major regions. During Q1 2025 the company reported net sales and profitability metrics for its main segments, pointing to ongoing demand for intensive care equipment and surgical workflows solutions, according to its quarterly presentation dated April 19, 2025 on the investor site Getinge Q1 2025 presentation as of 04/19/2025. Performance in individual product categories can vary depending on hospital investment priorities and public funding programs.

In acute care, ventilators, anesthesia machines and monitoring systems are key growth drivers when hospitals modernize intensive care units or expand capacity. These projects tend to be lumpy but can be sizeable when large hospital networks or public health systems approve new budgets. The company’s positioning in circulatory support and heart-lung machines also connects it to complex surgical procedures, including cardiac surgery and extracorporeal life support, where high clinical stakes support demand for reliable equipment.

Another important pillar is surgical workflows, which includes operating tables, lights, ceiling supply units and integrated operating room solutions. Here, Getinge AB benefits from hospitals shifting to more digital, interconnected operating rooms where devices, imaging and documentation systems communicate smoothly. Such installations often involve both hardware and software components, adding complexity but also potential for higher-margin service and update revenue once systems are in place.

The life science and sterile reprocessing area includes washers, sterilizers and related solutions used by central sterile supply departments and laboratories. Regulations in many markets require stringent control and documentation of each instrument’s cleaning cycle, which supports demand for modern, software-supported systems. For Getinge AB, this translates into equipment sales, validation services and recurring revenue from maintenance, spare parts and accessories, creating a long-term relationship with customers beyond the initial installation.

Why Getinge AB matters for US investors

Although Getinge AB is based in Sweden and listed on Nasdaq Stockholm, its products are used by hospitals and research facilities worldwide, including North America. For US-oriented investors, the stock provides exposure to global hospital capital expenditure and to structural trends such as aging populations and the need for better intensive care and surgical infrastructure. Demand for ventilators, surgical equipment and sterile reprocessing is closely linked to healthcare spending patterns in both public and private systems, including in the United States.

Exchange rates play a role for US investors because the stock trades in Swedish krona and the company reports in that currency. Movements between the US dollar and the Swedish krona can therefore influence the translated value of any investment and may also affect reported figures when Getinge AB converts foreign sales into its reporting currency. Investors tracking the stock from the US often monitor both operational performance and currency developments alongside broader medtech sector trends.

Another factor relevant for US-focused portfolios is the competitive landscape. Getinge AB competes globally with large medical technology players that are well known to US investors. Its positioning in specialized segments such as operating room integration and sterile reprocessing offers diversification compared with more generalist healthcare equipment names. At the same time, procurement decisions by large hospital groups and health systems in the US can influence order intake and long-term service revenue for the company.

Conclusion

Getinge AB’s recent Q1 2025 report gives investors another data point on how demand for intensive care, surgical workflows and sterile reprocessing equipment is evolving after the pandemic years. The company’s business model combines cyclical capital equipment sales with more recurring service and consumables revenue, which can provide a degree of stability. For US-oriented investors, the stock offers targeted exposure to hospital investment trends worldwide and to specific medtech niches rather than broad pharmaceuticals or general healthcare. However, factors such as public healthcare budgets, procurement cycles, regulatory requirements and currency fluctuations remain key variables that can influence performance over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.